FDA approves Shire drug for rare swelling disorder

Published On 2018-08-27 04:15 GMT   |   Update On 2018-08-27 04:15 GMT

The U.S. Food and Drug Administration (FDA) approved a first of its kind drug from Shire Plc to treat patients aged 12 and older suffering from a rare hereditary disease that causes swelling.


The drug, Takhzyro, is expected to bring in blockbuster sales for Shire and is important to Japan’s Takeda Pharmaceutical Co Ltd, which plans to buy the Dublin-based rare disease specialist for $62 billion.


The monoclonal antibody, previously known by its chemical name lanadelumab, was approved here to treat patients with types I and II hereditary angioedema (HAE), a disease that affects about 1 in 50,000.


There are only a handful of treatments available for HAE, including some from the Shire. The disease affects people who have low levels of a certain protein and results in episodes of severe swelling in different areas such as the stomach, limbs, face, and throat.





(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)




Article Source : REUTERS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News